Company intelligence / Profile preview

NuanBio

Edinburgh, Scotland, United Kingdomventureradar.com ↗

Ownership: Private
Development stage: Preclinical

Overview

NuanBio is an early-stage European biotech company spun out from Cumulus Oncology, developing antibody and ADC-based therapeutics for cancer. Its lead program, NUA-1, is in early research for oncology indications.[3][4]

Therapeutic areas: Oncology
Modalities: AntibodiesAntibody-Drug Conjugates (ADCs)
Industry: Biotech

Drug pipeline

1 asset

NUA1

Preclinical

Partnerships

Cumulus Oncology (spinout/parent relationship)[4]

Beyond the preview

Go deeper on NuanBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuanBio.

Explore the full profile